Definition and clinical classification
Hypertensive disorders of pregnancy comprise chronic or pre-existing hypertension, gestational hypertension, and preeclampsia. Collectively, they affect approximately 5–15% of pregnancies worldwide and are major contributors to maternal, fetal, and neonatal morbidity and mortality. Their incidence has increased in parallel with older maternal age at first childbirth and the rising prevalence of obesity.
Gestational hypertension is defined in the supplied guideline material as blood pressure >140/90 mmHg on two separate occasions after 20 weeks of gestation. Preeclampsia is characterized by new-onset hypertension after 20 weeks, generally accompanied by proteinuria or evidence of maternal organ involvement. Proteinuria is defined as urinary protein excretion >300 mg over 24 hours or a protein–creatinine ratio ≥0.3. Preeclampsia may nevertheless be diagnosed without proteinuria when clinical symptoms or laboratory abnormalities indicate end-organ injury.
Eclampsia is the occurrence of new-onset seizures or coma in a pregnant woman with preeclampsia. HELLP syndrome—haemolysis, elevated liver enzymes or transaminases, and thrombocytopenia—is generally regarded as a severe preeclamptic phenotype or variant.
Pathophysiology
The precise mechanism of preeclampsia remains incompletely established. Proposed contributors include chronic uteroplacental ischaemia, an exaggerated maternal inflammatory response, and disturbed angiogenic signalling.
A central biochemical feature is an imbalance between antiangiogenic and angiogenic factors. Placental production of soluble fms-like tyrosine kinase 1 increases, whereas placental growth factor production decreases. A circulating soluble fms-like tyrosine kinase 1/placental growth factor ratio ≥40 is associated with increased risk of preeclampsia with severe features during the subsequent two weeks.
Cerebral circulatory autoregulation is also disturbed. This helps explain the neurological manifestations of preeclampsia and the potential for stroke even at blood pressure levels that might otherwise be considered only moderately elevated.
The syndrome can produce widespread maternal complications, including pulmonary oedema, renal insufficiency, hepatic injury, thrombocytopenia, coagulopathy, cerebrovascular events, hepatic capsule rupture, placental abruption, disseminated intravascular coagulation, and multiple-organ failure. In the absence of treatment, approximately 1 in 100 cases of preeclampsia may progress to eclampsia.
Clinical presentation and symptoms
The clinical spectrum ranges from hypertension without apparent organ injury to severe multisystem disease. Severe features include:
Severe hypertension, defined as blood pressure ≥160/110 mmHg
Headache that does not respond to medication
Visual disturbance
Persistent severe epigastric pain
Pulmonary oedema
Thrombocytopenia, with platelets <100 × 10⁹/L
Renal insufficiency, with creatinine >1.1 mg/dL
Hepatic impairment, reflected by transaminase concentrations at least twice the normal level
Neurological symptoms are particularly important because of the increased risk of cerebrovascular complications. Seizures in a patient with preeclampsia indicate eclampsia.
Postpartum disease is clinically important. Hypertension is most frequent in women who had antenatal hypertensive disorders, but it may also arise de novo after delivery. New-onset postpartum preeclampsia is increasingly recognized as a significant cause of maternal morbidity and mortality during the postpartum period.
Maternal and obstetric complications
Immediate maternal complications include placental abruption, stroke, multiple-organ failure, disseminated intravascular coagulation, pulmonary oedema, hepatic complications, renal impairment, and cerebrovascular accidents. HELLP syndrome is associated with substantial morbidity and mortality.
Pregnancy-related hypertension also influences obstetric management. In late-preterm preeclampsia between 34 and 37 weeks, planned delivery within 48 hours was associated with lower maternal morbidity and less severe maternal hypertension, although neonatal intensive-care admission was more frequent. Timing of delivery therefore requires individualized assessment of maternal and fetal condition.
When hypertension is well controlled and not accompanied by severe features, delivery is planned around 39 weeks according to the supplied material. Mode of delivery should reflect gestational age, fetal assessment, the clinical circumstances, and maternal preference. Continuous fetal monitoring is required when induction of labour is undertaken. Neuraxial anaesthesia may be beneficial in severe preeclampsia by reducing the hypertensive response to pain and providing anaesthesia if caesarean delivery becomes necessary.
Long-term cardiovascular implications
A hypertensive disorder of pregnancy is not merely a transient obstetric diagnosis. It identifies women with increased future cardiovascular risk, particularly when the disorder is preeclampsia.
Women with a history of hypertensive disorders of pregnancy have approximately twice the long-term cardiovascular risk of women without such a history. The relative risk may be greater in younger women than in older pregnant women. Although much of the excess risk is explained by conventional risk factors, not all of it is accounted for in this way.
Preeclampsia
Preeclampsia occurs in approximately 1–2% of pregnancies in one guideline source and approximately 5–7% in another source within the supplied material. Compared with women without preeclampsia, affected women have an estimated 1.5- to 2.7-fold increase in cardiovascular disease risk.
Preeclampsia is also associated with a marked increase in future hypertension, with the reported relative risk approximately 3, and a more than two-fold increase in future diabetes mellitus. Later cardiovascular disease includes coronary artery disease, stroke, and heart failure.
Gestational hypertension and other hypertensive disorders
Pregnancy-related hypertension without preeclampsia is associated with a subsequent cardiovascular disease relative risk of approximately 1.7–2.5. The likelihood of sustained or future hypertension is increased, with reported relative risks ranging from 2.0 to 7.2 or higher. Future diabetes mellitus is also more common, with a reported relative risk of approximately 1.6–2.0.
Hypertensive disorders of pregnancy are additionally associated with increased later risk of hypertension, diabetes, heart failure, valvular disease, peripartum cardiomyopathy, stroke, and death.
Gestational diabetes
Gestational diabetes confers a particularly high risk of subsequent diabetes mellitus. Up to 50% of affected women may develop diabetes within five years after pregnancy. Gestational diabetes is associated with an approximately two-fold increase in future cardiovascular disease risk and is independently associated with an approximately two-fold increase in the long-term relative risk of cardiovascular events.
Other adverse pregnancy outcomes
Preterm delivery and stillbirth are associated with a moderate elevation in later cardiovascular risk. The supplied material reports a relative risk of approximately 1.6 after preterm delivery and 1.5 after stillbirth. Other guideline material describes preterm delivery, recurrent miscarriage, and one or more stillbirths as associated with approximately a 40% increase in long-term cardiovascular risk.
These pregnancy complications may therefore act as early markers of adverse vascular or metabolic health, especially in younger women whose conventional risk scores may otherwise appear reassuring.
Evaluation and physical examination
A comprehensive pregnancy history should form part of cardiovascular risk assessment in women. Relevant events include:
Gestational hypertension
Preeclampsia
HELLP syndrome
Gestational diabetes
Preterm delivery
Stillbirth
Recurrent miscarriage
Small-for-gestational-age infant
The history should establish the gestational age at onset, severity, presence of proteinuria or organ dysfunction, need for early delivery, postpartum persistence of hypertension, and any subsequent diagnosis of hypertension or diabetes. The supplied material does not provide a detailed physical-examination protocol for long-term assessment.
During and immediately after pregnancy, assessment should focus on blood pressure and symptoms indicating severe disease, including headache, visual symptoms, epigastric pain, dyspnoea suggestive of pulmonary oedema, and neurological manifestations. Postpartum blood pressure monitoring should be performed with ambulatory or home measurements when appropriate.
Diagnostics
Blood pressure
Blood pressure measurement is central to diagnosis and follow-up. Gestational hypertension is identified by blood pressure >140/90 mmHg on two separate occasions after 20 weeks. Severe hypertension is ≥160/110 mmHg.
Postpartum hypertension is specifically highlighted when blood pressure exceeds 150/100 mmHg; treatment should be continued in women with hypertension at this level after delivery.
Urinary assessment
Proteinuria supports the diagnosis of preeclampsia. Diagnostic thresholds provided are:
24-hour urinary protein >300 mg
Urine protein–creatinine ratio ≥0.3
Preeclampsia can be diagnosed without proteinuria if symptoms or laboratory findings indicate maternal end-organ involvement.
Laboratory assessment
The supplied material identifies the following laboratory indicators of severe disease:
Platelet count <100 × 10⁹/L
Creatinine >1.1 mg/dL
Transaminases at least twice the normal concentration
Evidence of haemolysis, elevated liver enzymes, and low platelets in HELLP syndrome
Angiogenic biomarkers
The soluble fms-like tyrosine kinase 1/placental growth factor ratio may assist in assessing risk. A ratio ≥40 is associated with increased risk of preeclampsia with severe features within the following two weeks.
The source material does not provide a broader diagnostic imaging or electrophysiological strategy for hypertensive pregnancy disorders or their long-term cardiovascular consequences.
Biomarkers and laboratory findings
The principal laboratory abnormalities associated with severe preeclampsia are thrombocytopenia, renal impairment, and hepatic injury. HELLP syndrome adds haemolysis to the combination of thrombocytopenia and elevated liver enzymes.
The angiogenic profile is characterized by increased soluble fms-like tyrosine kinase 1 and reduced placental growth factor. The source material does not specify reference concentrations or additional biomarker thresholds beyond the soluble fms-like tyrosine kinase 1/placental growth factor ratio of ≥40.
For long-term metabolic surveillance after gestational diabetes, fasting glucose or HbA1c may be preferable to oral glucose tolerance testing according to the supplied guideline material.
Prevention and treatment
Antenatal prevention
Low-dose aspirin initiated between 12 and 14 weeks of gestation reduces the risk of preeclampsia in women at high risk. The supplied material does not state the aspirin dose or provide a complete risk-based eligibility scheme.
Management of hypertension and preeclampsia
Management depends on disease severity, gestational age, and maternal and fetal status. In women with gestational hypertension or preeclampsia, the choice between delivery and expectant management should be guided by the presence or absence of severe features and by gestational age.
Severe hypertension and severe preeclampsia require urgent maternal and fetal assessment and management. The source material does not provide a complete acute antihypertensive dosing algorithm, a magnesium sulfate regimen, or a detailed fluid-management protocol.
Delivery
For late-preterm preeclampsia at 34–37 weeks, delivery planned within 48 hours may reduce maternal morbidity and severe hypertension, but neonatal intensive-care admission may increase. Decisions must therefore be individualized.
In otherwise well-managed hypertension without severe features, delivery should be planned at approximately 39 weeks. Continuous fetal monitoring is required during induction. Neuraxial anaesthesia is beneficial in severe preeclampsia because it may attenuate the hypertensive response to pain and provide anaesthesia if operative delivery is required.
Postpartum treatment
Uncomplicated postpartum hypertension during the first six weeks after delivery can be treated with nifedipine or labetalol; metoprolol is an alternative when labetalol is unavailable.
For acute severe postpartum hypertension, the agents listed are:
Labetalol
Hydralazine
Nifedipine
A short course of furosemide during the first five postpartum days in women with gestational hypertension or preeclampsia reduced the prevalence of persistently elevated blood pressure at seven days in a small randomized trial described in the source material.
Methyldopa should be avoided postpartum because of concern about postpartum depression. If used during pregnancy, it should be discontinued within two days after delivery and replaced with an alternative. Persistent postpartum hypertension should be treated with consideration of lactation status and current guidance.
Guideline-based cardiovascular prevention after pregnancy
Women with previous gestational hypertension or preeclampsia require longitudinal follow-up and modification of cardiovascular risk factors. Screening for later hypertension and diabetes is considered strongly justified, particularly after preeclampsia, despite the absence of a separate risk model specifically for women with hypertensive disorders of pregnancy.
Pregnancy-related complications can be used as non-traditional cardiovascular risk modifiers. A history of gestational hypertension, preeclampsia, gestational diabetes, preterm delivery, stillbirth, or recurrent miscarriage may justify upward reclassification of women with elevated blood pressure and borderline increased 10-year predicted cardiovascular risk, defined in the supplied material as 5% to <10%. This may influence risk-based decisions regarding blood-pressure-lowering therapy.
Premature menopause and preeclampsia are described as female-specific risk-enhancing factors with an effect on cardiovascular risk similar to standard risk factors. Other conditions, including infertility and polycystic ovary syndrome, have insufficient evidence in the supplied material to determine whether they should alter risk-based blood-pressure treatment decisions.
Follow-up and surveillance
Postpartum surveillance should include ambulatory and/or home blood pressure monitoring. Treatment should be continued in women with postpartum hypertension >150/100 mmHg. Because postpartum preeclampsia may arise de novo, surveillance should not be restricted to women with antenatal hypertension.
Longitudinal care should assess for:
Persistent or recurrent hypertension
Diabetes mellitus, particularly after gestational diabetes or preeclampsia
Other conventional cardiovascular risk factors
Cardiovascular complications such as coronary artery disease, stroke, and heart failure
Women with a history of hypertensive pregnancy disorders should receive risk-factor modification and ongoing cardiovascular follow-up. The supplied material does not specify exact follow-up intervals or a standardized testing schedule.
Prognosis
The prognosis is determined by the severity and timing of the pregnancy disorder, the presence of severe maternal features, fetal and obstetric status, and whether hypertension or metabolic disease persists after pregnancy.
Preeclampsia and gestational hypertension identify women at increased lifetime risk of hypertension, diabetes, coronary artery disease, stroke, and heart failure. Gestational diabetes particularly predicts future diabetes, with up to half of affected women developing diabetes within five years. Preterm delivery and stillbirth also signal elevated future cardiovascular risk.
The recognition of these complications provides an opportunity for earlier cardiovascular prevention. Their importance is greatest in younger women, in whom conventional risk calculators may underestimate lifetime risk because of age despite a clinically meaningful history of pregnancy-related vascular disease.
